• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association of body mass index with COVID-19-related neurologic sequelae: a retrospective cohort study
This study demonstrates the absence of an association between BMI and neurologic manifestations following acute COVID-19 illness. Prospective studies using standardized data collection tools and direct measures of body fat are warranted to obtain more valid effect estimates.
Source: Clinical and Experimental Medicine - December 16, 2022 Category: Research Source Type: research

Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Eur Respir Rev. 2022 Nov 2;31(166):220098. doi: 10.1183/16000617.0098-2022. Print 2022 Dec 31.ABSTRACTBACKGROUND: As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations.METHODS: We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to sever...
Source: Respiratory Care - November 2, 2022 Category: Respiratory Medicine Authors: Constantine I Vardavas Alexander G Mathioudakis Katerina Nikitara Kimon Stamatelopoulos Georgios Georgiopoulos Revati Phalkey Jo Leonardi-Bee Esteve Fernandez Dolors Carnicer-Pont J ørgen Vestbo Jan C Semenza Charlotte Deogan Jonathan E Suk Piotr Kramarz Source Type: research

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Lancet Respir Med. 2021 Jul 27:S2213-2600(21)00310-6. doi: 10.1016/S2213-2600(21)00310-6. Online ahead of print.ABSTRACTBACKGROUND: Doxycycline is often used for treating COVID-19 respiratory symptoms in the community despite an absence of evidence from clinical trials to support its use. We aimed to assess the efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse outcomes.METHODS: We did a national, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in older people (PRINCIPLE) across primary care centres in the UK. We included peo...
Source: Respiratory Care - July 30, 2021 Category: Respiratory Medicine Authors: Christopher C Butler Ly-Mee Yu Jienchi Dorward Oghenekome Gbinigie Gail Hayward Benjamin R Saville Oliver Van Hecke Nicholas Berry Michelle A Detry Christina Saunders Mark Fitzgerald Victoria Harris Ratko Djukanovic Stephan Gadola John Kirkpatrick Simon d Source Type: research